PubRank

Steven C Clifford

Author PubWeight™ 100.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2010 8.06
2 Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2011 6.67
3 Subtypes of medulloblastoma have distinct developmental origins. Nature 2010 5.94
4 Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 2008 5.86
5 Dissecting the genomic complexity underlying medulloblastoma. Nature 2012 4.77
6 Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012 4.13
7 Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012 3.88
8 beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005 2.84
9 Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 2011 2.82
10 Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol 2012 2.34
11 The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 2005 2.14
12 Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2010 2.04
13 Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 2012 2.01
14 Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 2011 2.01
15 Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 2002 1.71
16 Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004 1.67
17 Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior. Brain Pathol 2007 1.59
18 Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 2014 1.56
19 PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 2003 1.46
20 Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013 1.43
21 Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. Genes Chromosomes Cancer 2006 1.35
22 MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol 2011 1.33
23 Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 2011 1.33
24 Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PLoS One 2009 1.33
25 Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol 2011 1.32
26 CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol 2014 1.28
27 DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 2013 1.27
28 The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br J Neurosurg 2009 1.27
29 Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 2009 1.25
30 The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma. Brain Res Mol Brain Res 2004 1.17
31 What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 2003 1.16
32 Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle 2009 1.13
33 Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 2003 1.13
34 Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol 2013 1.12
35 Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 2003 1.11
36 Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. Neuro Oncol 2011 1.10
37 Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro Oncol 2008 1.07
38 Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer 2006 1.00
39 Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res 2002 0.99
40 Epigenetic events in medulloblastoma development. Neurosurg Focus 2005 0.98
41 TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas. J Clin Oncol 2011 0.96
42 Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer 2006 0.91
43 Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death. Acta Neuropathol 2011 0.91
44 Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types. Acta Neuropathol 2013 0.89
45 Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett 2004 0.87
46 Identification of a neuronal transcription factor network involved in medulloblastoma development. Acta Neuropathol Commun 2013 0.85
47 Chromosome 1q gain is not associated with a poor outcome in childhood medulloblastoma: requirements for the validation of potential prognostic biomarkers. Cell Cycle 2009 0.85
48 Identification and analysis of tumor suppressor loci at chromosome 10q23.3-10q25.3 in medulloblastoma. Cell Cycle 2006 0.85
49 Genome-wide analysis of alternative splicing in medulloblastoma identifies splicing patterns characteristic of normal cerebellar development. Cancer Res 2011 0.83
50 TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours. Acta Neuropathol 2013 0.83
51 Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells. Haematologica 2013 0.82
52 Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system. J Neurooncol 2013 0.81
53 RASSF1A and the BH3-only mimetic ABT-737 promote apoptosis in pediatric medulloblastoma cell lines. Neuro Oncol 2011 0.80
54 Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpoint. Genes Chromosomes Cancer 2009 0.79
55 WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun 2014 0.79
56 Cancer genetics: Evolution after tumour spread. Nature 2012 0.78
57 Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics 2015 0.78
58 Improved health-related quality of life outcomes associated with SHH subgroup medulloblastoma in SIOP-UKCCSG PNET3 trial survivors. Acta Neuropathol 2014 0.77
59 APC and CTNNB1 mutations are rare in sporadic ependymomas. Cancer Genet Cytogenet 2006 0.76
60 A 7-year-old boy with midline cerebellar mass. Brain Pathol 2005 0.75
61 The importance of biopsy following radiological diagnosis of relapsed medulloblastoma. Br J Neurosurg 2011 0.75